Zobrazeno 1 - 10 of 232 pro vyhledávání: '"Gevensleben, H"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
Autor: Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner N, Ruddle R, Raynaud F, Decordova S, Swales K, Finneran L, Hall E, Rugman P, Lindemann J, Foxley A, Lord C, Banerji U, Plummer R, Basu B, Lopez J, Drew Y, de Bono J
Publikováno v: Cancer Discovery
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Preclinical studies have demonstrated synergy between poly(ADP-ribose) polymerase (PARP) and phosphatidylinositol-3-kinase (PI3K)/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigato
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::427df1bb8636f3a22173a38097ca6bf8
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4544
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Autor: Mavaddat, N., Barrowdale, D., Andrulis, I.L., Domchek, S.M., Eccles, D., Nevanlinna, H., Ramus, S.J., Spurdle, A., Robson, M., Sherman, M., Mulligan, A.M., Couch, F.J., Engel, C., McGuffog, L., Healey, S., Sinilnikova, O.M., Southey, M.C., Terry, M.B., Goldgar, D., O'Malley, F., John, E.M., Janavicius, R., Tihomirova, L., Hansen, T.V.O., Nielsen, F.C., Osorio, A., Stavropoulou, A., Benitez, J., Manoukian, S., Peissel, B., Barile, M., Volorio, S., Pasini, B., Dolcetti, R., Putignano, A.L., Ottini, L., Radice, P., Hamann, U., Rashid, M.U., Hogervorst, F.B., Kriege, M., Luijt, R.B. van der, Peock, S., Frost, D., Evans, D.G., Brewer, C., Walker, L., Rogers, M.T., Side, L.E., Houghton, C., Weaver, J., Godwin, A.K., Schmutzler, R.K., Wappenschmidt, B., Meindl, A., Kast, K., Arnold, N., Niederacher, D., Sutter, C., Deissler, H., Gadzicki, D., Preisler-Adams, S., Varon-Mateeva, R., Schonbuchner, I., Gevensleben, H., Stoppa-Lyonnet, D., Belotti, M., Barjhoux, L., Isaacs, C., Peshkin, B.N., Caldes, T., Hoya, M. de la, Canadas, C., Heikkinen, T., Heikkila, P., Aittomaki, K., Blanco, I., Lazaro, C., Brunet, J., Agnarsson, B.A., Arason, A., Barkardottir, R.B., Dumont, M., Simard, J., Montagna, M., Agata, S., D'Andrea, E., Yan, M., Fox, S., Rebbeck, T.R., Rubinstein, W., Tung, N., Garber, J.E., Wang, X.S., Fredericksen, Z., Pankratz, V.S., Lindor, N.M., Szabo, C., Offit, K., Sakr, R., Gaudet, M.M., Singer, C.F., Tea, M.K., Rappaport, C., Mai, P.L., Greene, M.H., Sokolenko, A., Imyanitov, E., Toland, A.E., Senter, L., Sweet, K., Thomassen, M., Gerdes, A.M., Kruse, T., Caligo, M., Aretini, P., Rantala, J., Wachenfeld, A. von, Henriksson, K., Steele, L., Neuhausen, S.L., Nussbaum, R., Beattie, M., Odunsi, K., Sucheston, L., Gayther, S.A., Nathanson, K., Gross, J., Walsh, C., Karlan, B., Chenevix-Trench, G., Easton, D.F., Antoniou, A.C., HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, SWE-BRCA Collaborators, Consortium Investigators Modifiers
Publikováno v: Cancer Epidemiology Biomarkers & Prevention; Vol 21
Cancer Epidemiology Biomarkers & Prevention, 21(1), 134-147. American Association for Cancer Research Inc.
Cancer Epidemiology, Biomarkers & Prevention, 21, 1, pp. 134-47
Cancer Epidemiology, Biomarkers and Prevention, 21(1), 134-147
Cancer Epidemiology, Biomarkers & Prevention, 21, 134-47
Mavaddat, N, Barrowdale, D, Andrulis, I L, Domchek, S M, Eccles, D, Nevanlinna, H, Ramus, S J, Spurdle, A, Robson, M, Sherman, M, Mulligan, A M, Couch, F J, Engel, C, McGuffog, L, Healey, S, Sinilnikova, O M, Southey, M C, Terry, M B, Goldgar, D, O'Malley, F, John, E M, Janavicius, R, Tihomirova, L, Hansen, T V O, Nielsen, F C, Osorio, A, Stavropoulou, A, Benítez, J, Manoukian, S, Peissel, B, Barile, M, Volorio, S, Pasini, B, Dolcetti, R, Putignano, A L, Ottini, L, Radice, P, Hamann, U, Rashid, M U, Hogervorst, F B, Kriege, M, van der Luijt, R B, Peock, S, Frost, D, Evans, D G, Brewer, C, Walker, L, Thomassen, M, Gerdes, A-M, Kruse, T & for HEBON 2011, ' Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) ', Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 1, pp. 134-47 . https://doi.org/10.1158/1055-9965.EPI-11-0775
Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05310148e4e4486e517e1140cc99edc0
https://hdl.handle.net/1887/97446
Zobrazit plný text záznamu
10
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
Autor: Mulligan, AM, Couch, FJ, Barrowdale, D, Domchek, SM, Eccles, D, Nevanlinna, H, Ramus, SJ, Robson, M, Sherman, M, Spurdle, AB, Wappenschmidt, B, Lee, A, McGuffog, L, Healey, S, Sinilnikova, OM, Janavicius, R, Hansen, TV, Nielsen, FC, Ejlertsen, B, Osorio, A, Muñoz-Repeto, I, Durán, M, Godino, J, Pertesi, M, Benítez, J, Peterlongo, P, Manoukian, S, Peissel, B, Zaffaroni, D, Cattaneo, E, Bonanni, B, Viel, A, Pasini, B, Papi, L, Ottini, L, Savarese, A, Bernard, L, Radice, P, Hamann, U, Verheus, M, Meijers-Heijboer, HEJ, Wijnen, J, Gómez García, EB, Nelen, MR, Kets, CM, Seynaeve, C, Tilanus-Linthorst, MMA, van der Luijt, RB, Os, TV, Rookus, M, Frost, D, Jones, JL, Evans, DG, Lalloo, F, Eeles, R, Izatt, L, Adlard, J, Davidson, R, Cook, J, Donaldson, A, Dorkins, H, Gregory, H, Eason, J, Houghton, C, Barwell, J, Side, LE, McCann, E, Murray, A, Peock, S, Godwin, AK, Schmutzler, RK, Rhiem, K, Engel, C, Meindl, A, Ruehl, I, Arnold, N, Niederacher, D, Sutter, C, Deissler, H, Gadzicki, D, Kast, K, Preisler-Adams, S, Varon-Mateeva, R, Schoenbuchner, I, Fiebig, B, Heinritz, W, Schäfer, D, Gevensleben, H, Caux-Moncoutier, V
Publikováno v: Mulligan, AM; Couch, FJ; Barrowdale, D; Domchek, SM; Eccles, D; Nevanlinna, H; et al.(2011). Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 13(6). doi: 10.1186/bcr3052. UCLA: Retrieved from: http://www.escholarship.org/uc/item/54c4p0f3
Introduction: Previous studies have demonstrated that common breast cancer susceptibility alleles are differentially associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. It is currently unknown how these alleles are associated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ff93be651cdfeb9aec11287c84d9098c
http://www.escholarship.org/uc/item/54c4p0f3
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje